DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l6cbkv/cell_based_assays) has announced the addition of the "Cell Based Assays Market" report to their offering.
The global cell-based assays market is expected to grow approximately $15 billion by 2018 at a CAGR of 11%. North America reported largest market share, followed by Europe, and Asia is expected to be the fastest growing region for increasing investments in life science research, advancements in technology and drug discovery outsourcing.
Increase in investments by pharmaceutical companies in drug discovery, replacement of in vivo toxicity testing by in vitro testing methods, adoption of cell assay based on high throughput assay
(HTS) screening, low cost label-free technology, accurate results, preference over animal model and emergence of new technologies such as microfluidics are some of the major drivers. Whereas, intellectual property rights deprived innovation which hampered market growth. Emerging areas such as advancement in stem cell culture, induced pluripotent stem cells, 3D cell based assay, single-cell assay, need of toxicity screening were opportunistic factors, while complexity of HTS assay, assay standardization and validation were threats. Major challenge was to optimize assay for cell-based assay.
Key Topics Covered:
1. Executive Summary
3. Market Analysis
4. Cell-based assays market, by Applications
5. Cell-based assays market, by Products
6. Cell-based assays market, by End-users
7. Regional Market Analysis
8. Company Developments
9. Major Company Profiles
- BD Bioscience
- Beckman Coulter
- Danaher Corporation
- EMD Millipore
- GE Healthcare
- Invitrogen Corporation
- Life technologies corporation
- Perkin Elmer
- Promega Corporation
For more information visit http://www.researchandmarkets.com/research/l6cbkv/cell_based_assays